Compare Southern Copper Corp (SCCO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs TG Therapeutics Inc — how do they compare? Southern Copper Corp trades at $187.95 (market cap $146.07B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Southern Copper Corp is far larger — about 17.7× TG Therapeutics Inc's market cap, and Southern Copper Corp pays a 2.28% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SCCO | TGTX | |
|---|---|---|
Market Cap | $146.07B | $8.26B |
Sector | Basic Materials | Health |
52-Week High | $218.85 | $59.06 |
52-Week Low | $90.54 | $26.39 |
Enterprise Value | $148.12B | $8.50B |
Dividend Yield | 2.28% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
